Transverse myelitis (TM) is a rare neurological disease characterized by inflammation of the spinal cord. The condition causes symptoms that are varied and unpredictable, posing challenges for patients and healthcare providers. This article will take a closer look at the causes, symptoms, and pathological mechanisms behind transverse myelitis and reveal why these symptoms can be so variable.
The exact cause of transverse myelitis is not known. But many studies have shown that it may be related to different infections, immune system diseases or damage to nerve fibers.
In 60% of TM patients, the cause is unknown. Other rare causes may include meningitis and autoimmune reactions associated with neurospinal photosensitivity.
Viruses are a major risk factor for transverse myelitis, especially HIV, herpes simplex, and herpes zoster. In addition, bacterial infections such as Mycoplasma pneumoniae and Lyme disease have also been linked to transverse myelitis.
Symptoms of transverse myelitis typically include limb weakness and numbness, loss of sensory and motor skills, urinary and anal sphincter dysfunction, and autonomic nervous system insufficiency. Symptoms may develop over a period of hours to weeks, and their severity often depends on the size and depth of the spinal cord affected.
Symptoms can vary widely, and patients may experience a tingling sensation like pins and needles in their feet. This is because the inflammation affects different areas of the sensory nerves.
If the upper cervical segment of the spinal cord is affected, the limbs may be affected and even risk respiratory failure; if the thoracic spine is affected, the common symptom is spastic paralysis of the lower limbs.
Diagnosis of transverse myelitis usually requires a specialized neurological examination and imaging techniques (such as MRI) to determine the extent of the lesion. In terms of treatment, early intervention can improve the patient's prognosis. Common treatments include high doses of steroids to reduce inflammation and swelling of the spinal cord.
In some cases, plasma exchange therapy (PP) can also bring certain positive effects to patients, and the improvement may last even for several weeks after treatment.
Different causes will affect treatment strategies, and the extent of recovery varies greatly between individuals. Some patients may begin to recover in two to twelve weeks and may continue to improve for up to two years.
The prognosis for transverse myelitis depends on whether the person improves within three to six months. If there is no progression, the likelihood of full recovery is low. About one-third of patients achieve full recovery, one-third experience significant neurological deficits, and the remaining one-third do not recover at all.
According to research, the annual incidence of TM is about 4.6 cases per million people. It can occur in people of all ages, but is more common in people in their teens, twenties, and forties and above.
Transverse myelitis has been around and recognized for many years, but more recently celebrities have contributed to public awareness of the condition, particularly the former Slipknot drummer.
While our understanding of transverse myelitis has improved, the variability of its symptoms continues to cause considerable confusion for patients and healthcare professionals. Faced with this challenge, how can we better deal with this complex disease?